CLEVELAND, Ohio (Ivanhoe Newswire)— New year, new chance to improve your eating habits. But if you’re taking prescription supplements to improve your heart health, new research suggests there’s one popular pill that can come off your list.
Fish oil products, containing the “good fats” from fish, have long been thought to improve heart health. Despite earlier FDA approval, scientists at the Cleveland Clinic say new research examined the benefits of prescription-strength fish oil pills.
“This is a drug that is like the fish oil people buy over-the-counter, but much, much more effective. It has a higher amount of what we call omega-3 fatty acids which is the active component in fish oil,” explained Steven Nissen, MD, Chief Academic Officer of the Heart, Vascular & Thoracic Institute at Cleveland Clinic.
In a randomized trial of 13,000 patients called the STRENGTH trial, some participants received daily, high-dose omega-3 supplements. Others received a placebo made from corn oil, which is used in cooking. Researchers found the prescription omega-3 fatty acid did not reduce cardiovascular events like heart attack.
“It’s really kind of a wake-up call when you see a study like this where the most potent, prescription-grade fish oil didn’t have any favorable effects,” illustrated Dr. Nissen.
In fact, the STRENGTH trial showed a 69 percent increase in atrial fibrillation in the group that took the high dose omega-3. Scientists say the findings indicate these products should undergo additional review.
Dr. Nissen says the results of the STRENGTH trial have implications for over-the-counter fish oil products since many people take large doses to avoid the expense of prescription fish oil.
Contributors to this news report include: Cyndy McGrath, Executive & Field Producer; Roque Correa, Editor.
To receive a free weekly e-mail on Medical Breakthroughs from Ivanhoe, sign up at: http://www.ivanhoe.com/ftk
TOPIC: OMEGA-3 FISH OIL NO HELP FOR HEART HEALTH?
REPORT: MB #4848
BACKGROUND: Omega-3 fatty acids are one of the two major classes of polyunsaturated fatty acids, also called PUFAs, that consist of long chains of carbon atoms with a carboxyl group at one end of the chain and a methyl group at the other. PUFAs are different than saturated fatty acids in that they have two or more double bonds between carbons within the fatty acid chain. The majority of scientific research on the potential health benefits of consuming Omega-3s is focused on dietary supplements like fish oil. Studies had linked higher intakes of fish and other seafood with improved health outcomes. However, it is still difficult to determine if this is exclusively because of the presence of the omega-3 fatty acids or if other elements of seafood nutrients are responsible.
IMPLICATIONS: Many people take omega-3 fish oil supplements to promote heart health. For many years, the American Heart Association has recommended eating two servings of fish a week and in 2017 the association also recommended taking supplements to slightly lower the risk of dying after or heart failure or recent heart attack. However, they also stated that these supplements do not prevent heart disease. One of the common heart health complications people attempt to treat with omega-3s is atrial fibrillation, or AFib, an irregular or “quivering” heartbeat. More than 33 million people worldwide are currently affected by this condition and are at higher risk for stroke and heart failure. In a study of nearly 26,000 with no previous heart problems, one group received 840 mg of omega-3 fatty acids, and another received placebo. Over five years the researchers documented 900 AFib events and found that events were not exclusive to omega-3 use. Thus, concluding that the omega-3 supplements had no effect in preventing atrial fibrillation.
NEW RESEARCH: A new study from the Cleveland Clinic confirms the results of the previous study as well as indicates possible negative effects. The STRENGTH trial consisted of 13,078 patients also randomized to either receive high-dose omega-3s, equivalent to a prescription-strength supplement, or placebo. The trial initially had neutral results showing no significant reduction in major adverse cardiovascular events for either group. Then a double-blind multicenter trial took place including patients who were randomized at 675 different hospitals in North America, Europe, South America, Asia, Australia, New Zealand, and South Africa. The patients received either 4g daily of omega-3 carboxylic acid (CA) or a placebo of corn oil. The primary endpoint events consisted of cardiovascular death, non-fatal heart attack, non-fatal stroke, coronary artery revascularization, and hospitalization for unstable angina. The trial was stopped by the monitoring committee after 1,384 patients experienced a primary endpoint event. The research determined no clinical benefits of omega-3 CA compared to placebo and found that omega-3 CA actually resulted in a 67 percent increase in atrial fibrillation.
FOR MORE INFORMATION ON THIS REPORT, PLEASE CONTACT:
If this story or any other Ivanhoe story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Marjorie Bekaert Thomas at firstname.lastname@example.org